ArticleArchives of virology2026
Integrated in silico-in vitro identification of high-affinity TCR-Like antibodies targeting HPV18 E6/E7 for cervical cancer detection.
Article in Archives of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The aim of this study was to evaluate the diagnostic potential of human papillomavirus type 18 (HPV18) E6/E7-specific T cell receptor (TCR)-like antibodies for the early detection of HPV-associated cervical cancer. An integrated in silico and in vitro approach was employed, in which three fully human TCR-like antibodies (H11\Ab, E5\Ab, and G8\Ab) were analysed by molecular docking to assess antibody-peptide-major histocompatibility complex (P-MHC) class I HLA-A24:02 interactions, followed by experimental validation using SiHa and C33A cervical cancer cell lines. Docking analyses demonstrated stable, high-affinity interactions between the antibodies and their corresponding peptide-MHC complexes, consistent with experimental observations. In vitro assays confirmed strong binding specificity and functional activity in HPV18-positive cells, with no detectable reactivity in HPV-negative controls. These findings demonstrate that TCR-like antibodies targeting HPV18 E6/E7 peptide-MHC complexes enable highly specific detection of HPV-associated cervical cancer and support their potential application as early diagnostic biomarkers.
Indexed as
Identifiers
42113290What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.